Filing Flows › ImmunityBio (IBRX) › Q1 2025
ImmunityBio (IBRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
ImmunityBio (IBRX) reported revenue of $16.5M for the first quarter 2025 (Q1 2025), up 413-fold from a year earlier and +119% from the quarter before. Operating margin was -390.1%, net loss $130M (785.0% of revenue).
ImmunityBio, Q1 2025: revenue $16.5M (413× year over year), operating margin -390.1%, net loss $130M, operating cash flow −$85.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.5M | +119% | 413× |
| Operating profit | −$64.4M | — | — |
| Net earnings | −$130M | — | — |
| Operating cash flow | −$85.9M | — | — |
What changed
Revenue was $16.5M in Q1 2025, up 41192% year over year and up 119% from the previous quarter. Product revenue, net was the largest line at 100% of revenue. Other revenues declined 80%.
Operating costs exceeded revenue by $64.4M, an operating margin of -390.1%. Total costs fell 15% while revenue rose 41192%. The quarter ended with a net loss of $129.7M, wider than the previous quarter's $59.2M loss. Minority interests bore $20K of it: to shareholders the quarter was a loss of $129.6M. Net interest and other expense of $65.5M was the main reason.
Operating cash flow was −$85.9M. Non-cash charges added back $3.8M of depreciation and amortization and $9.5M of share-based compensation. Working capital and other items added $30.4M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$87.0M.
Questions
What was ImmunityBio's revenue in the first quarter 2025?
ImmunityBio (IBRX) reported revenue of $16.5M for the first quarter 2025 (Q1 2025), up 413-fold from a year earlier and +119% from the quarter before.
Was ImmunityBio profitable in the first quarter 2025?
Operating loss was $64.4M (-390.1% of revenue) and net loss $130M.
Source: ImmunityBio 10-Q on SEC EDGAR.